{
 "cells": [
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": [
    "# GraphRAG Python\n",
    "End-to-End Example"
   ],
   "id": "cf0be1ddc2bd2434"
  },
  {
   "metadata": {},
   "cell_type": "code",
   "source": [
    "%%capture\n",
    "%pip install fsspec langchain-text-splitters openai python-dotenv numpy torch"
   ],
   "id": "9820f541adf30bfd",
   "outputs": [],
   "execution_count": null
  },
  {
   "metadata": {},
   "cell_type": "code",
   "source": [
    "%%capture\n",
    "%pip install -U git+https://github.com/neo4j/neo4j-graphrag-python"
   ],
   "id": "aa9e401e2305fb0",
   "outputs": [],
   "execution_count": null
  },
  {
   "metadata": {},
   "cell_type": "code",
   "source": [
    "#%capture\n",
    "#%pip install -U ../demo/neo4j-graphrag-python"
   ],
   "id": "fa8a46520d565af0",
   "outputs": [],
   "execution_count": null
  },
  {
   "metadata": {},
   "cell_type": "code",
   "source": [
    "from dotenv import load_dotenv\n",
    "import os\n",
    "\n",
    "# load neo4j credentials (and openai api key in background)\n",
    "load_dotenv('.env', override=True)\n",
    "NEO4J_URI = os.getenv('NEO4J_URI')\n",
    "NEO4J_USERNAME = os.getenv('NEO4J_USERNAME')\n",
    "NEO4J_PASSWORD = os.getenv('NEO4J_PASSWORD')\n",
    "\n",
    "pdf_file_path = \"pgpm-13-39.pdf\""
   ],
   "id": "a023c71324bf6e7f",
   "outputs": [],
   "execution_count": null
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "## KG Building\n",
   "id": "418bd212bae7f492"
  },
  {
   "metadata": {},
   "cell_type": "code",
   "source": [
    "import neo4j\n",
    "from neo4j_graphrag.llm import OpenAILLM\n",
    "\n",
    "driver = neo4j.GraphDatabase.driver(NEO4J_URI, auth=(NEO4J_USERNAME, NEO4J_PASSWORD))\n",
    "\n",
    "extractor_llm=OpenAILLM(\n",
    "    model_name=\"gpt-4o-mini\",\n",
    "    model_params={\n",
    "        \"max_tokens\": 16_000,\n",
    "        \"response_format\": {\"type\": \"json_object\"}, # use json_object formatting for best results\n",
    "        \"temperature\": 0 # turning temperature down for more deterministic results\n",
    "    }\n",
    ")"
   ],
   "id": "fd60a2f512b9701d",
   "outputs": [],
   "execution_count": null
  },
  {
   "metadata": {},
   "cell_type": "code",
   "source": [
    "#define node labels\n",
    "basic_node_labels = [\"Object\",\n",
    "                     \"Entity\",\n",
    "                     \"Group\",\n",
    "                     \"Person\",\n",
    "                     \"Organization\",\n",
    "                     \"Place\"]\n",
    "\n",
    "academic_node_labels = [\"ArticleOrPaper\",\n",
    "                        \"PublicationOrJournal\"]\n",
    "\n",
    "medical_node_labels = [\"Anatomy\",\n",
    "                       \"BiologicalProcess\",\n",
    "                       \"Cell\",\n",
    "                       \"CellularComponent\",\n",
    "                       \"CellType\",\n",
    "                       \"Condition\",\n",
    "                       \"Disease\",\n",
    "                       \"Drug\",\n",
    "                       \"EffectOrPhenotype\",\n",
    "                       \"Exposure\",\n",
    "                       \"GeneOrProtein\",\n",
    "                       \"Molecule\",\n",
    "                       \"MolecularFunction\",\n",
    "                       \"Pathway\"]\n",
    "\n",
    "node_labels = basic_node_labels + academic_node_labels + medical_node_labels\n",
    "\n",
    "# define relationship types\n",
    "rel_types = [\"ACTIVATES\",\n",
    "             \"AFFECTS\",\n",
    "             \"ASSESSES\",\n",
    "             \"ASSOCIATED_WITH\",\n",
    "             \"AUTHORED\",\n",
    "             \"CAUSES\",\n",
    "             \"CITES\",\n",
    "             \"CLASSIFIES\",\n",
    "             \"COLLABORATES_WITH\"\n",
    "             \"CONTRIBUTES_TO\",\n",
    "             \"CORRELATES_WITH\",\n",
    "             \"DESCRIBES\",\n",
    "             \"DEVELOPED\",\n",
    "             \"DISCUSSES\",\n",
    "             \"EXHIBITS\",\n",
    "             \"EXPRESSES\",\n",
    "             \"HAS_EFFECT\",\n",
    "             \"HAS_SYMPTOM\",\n",
    "             \"INCLUDES\",\n",
    "             \"INDUCES\",\n",
    "             \"INTERACTS_WITH\",\n",
    "             \"INVOLVES\",\n",
    "             \"LEADS_TO\",\n",
    "             \"LINKED_TO\",\n",
    "             \"LOCATED_IN\",\n",
    "             \"MANIFESTS_AS\",\n",
    "             \"OBSERVED_IN\",\n",
    "             \"PARTICIPATES_IN\",\n",
    "             \"PART_OF\",\n",
    "             \"PRODUCES\",\n",
    "             \"PUBLISHED_IN\",\n",
    "             \"REACTS_WITH\",\n",
    "             \"REDUCES\",\n",
    "             \"RELATED_TO\",\n",
    "             \"RESULTS_IN\",\n",
    "             \"TARGETS\",\n",
    "             \"TREATMENT_FOR\",\n",
    "             \"TRIGGERS\",\n",
    "             \"USED_FOR\",\n",
    "             \"USED_WITH\",\n",
    "             \"USES\"]\n"
   ],
   "id": "6cba83fa4638e21d",
   "outputs": [],
   "execution_count": null
  },
  {
   "metadata": {},
   "cell_type": "code",
   "source": [
    "prompt_template = '''\n",
    "You are a medical researcher tasks with extracting information from papers \n",
    "and structuring it in a property graph to inform further medical and research Q&A\n",
    "\n",
    "Extract the entities (nodes) and specify their type from the following Input text.\n",
    "Also extract the relationships between these nodes. the relationship direction goes from the start node to the end node. \n",
    "\n",
    "\n",
    "Return result as JSON using the following format:\n",
    "{{\"nodes\": [ {{\"id\": \"0\", \"label\": \"the type of entity\", \"properties\": {{\"name\": \"name of entity\", \"details\":\" brief description of entity (dont include info about relationships)\" }} }}],\n",
    "  \"relationships\": [{{\"type\": \"TYPE_OF_RELATIONSHIP\", \"start_node_id\": \"0\", \"end_node_id\": \"1\", \"properties\": {{\"details\": \"brief description of relationship if needed\"}} }}] }}\n",
    "\n",
    "Use only the information from the Input text.  Do not add any additional information.  If the input text is empty, return empty Json. \n",
    "Make sure to create as many nodes and relationships as needed to offer rich medical context for further research.\n",
    "An AI knowledge assistant must be able to read this graph and immediately understand the context to inform detailed research questions. \n",
    "\n",
    "Use only fhe following nodes and relationships (if provided):\n",
    "{schema}\n",
    "\n",
    "Assign a unique ID (string) to each node, and reuse it to define relationships.\n",
    "Do respect the source and target node types for relationship and\n",
    "the relationship direction.\n",
    "\n",
    "Do not return any additional information other than the JSON in it.\n",
    "\n",
    "Examples:\n",
    "{examples}\n",
    "\n",
    "Input text:\n",
    "\n",
    "{text}\n",
    "'''"
   ],
   "id": "8cbcdedcd1757b1d",
   "outputs": [],
   "execution_count": null
  },
  {
   "metadata": {},
   "cell_type": "code",
   "source": [
    "from langchain_text_splitters import CharacterTextSplitter\n",
    "from neo4j_graphrag.experimental.components.text_splitters.langchain import LangChainTextSplitterAdapter\n",
    "from neo4j_graphrag.experimental.pipeline.kg_builder import SimpleKGPipeline\n",
    "\n",
    "kg_builder_pdf = SimpleKGPipeline(\n",
    "    llm=extractor_llm,\n",
    "    driver=driver,\n",
    "    entities=node_labels,\n",
    "    relations=rel_types,\n",
    "    prompt_template=prompt_template,\n",
    "    #text_splitter=LangChainTextSplitterAdapter(CharacterTextSplitter(chunk_size=500, chunk_overlap=100, separator=\".\")),\n",
    "    from_pdf=True\n",
    ")"
   ],
   "id": "94e1dfac980e6527",
   "outputs": [],
   "execution_count": null
  },
  {
   "metadata": {},
   "cell_type": "code",
   "source": [
    "pdf_result = await kg_builder_pdf.run_async(file_path=pdf_file_path)\n",
    "print(f\"PDF Processing Result: {pdf_result}\")"
   ],
   "id": "edeee98826a970a8",
   "outputs": [],
   "execution_count": null
  },
  {
   "metadata": {},
   "cell_type": "code",
   "source": [
    "with neo4j.GraphDatabase.driver(NEO4J_URI, auth=(NEO4J_USERNAME, NEO4J_PASSWORD)) as driver:\n",
    "    with driver.session(database=\"neo4j\") as session:\n",
    "        session.run('''\n",
    "        MATCH (n:Chunk) WHERE size(n.text) <> 0\n",
    "        WITH collect(n) AS nodes, toInteger(rand()*$numberOfBatches) AS partition\n",
    "        CALL (nodes){\n",
    "            CALL genai.vector.encodeBatch([node IN nodes| node.text], \"OpenAI\", { token: $token})\n",
    "            YIELD index, vector\n",
    "            CALL db.create.setNodeVectorProperty(nodes[index], \"embedding\", vector)\n",
    "        } IN TRANSACTIONS OF 1 ROW''', parameters={'token':os.getenv('OPENAI_API_KEY'), 'numberOfBatches':2})"
   ],
   "id": "e86545113f04266d",
   "outputs": [],
   "execution_count": null
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": [
    "## KG Retrieval\n",
    "Now lets make some knowledge graph retrievers which we will later use for a GraphRAG pipeline"
   ],
   "id": "a9c0fd965b15b143"
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "We will leverage Neo4j's vector search capabilities here. To do this we need to begin by creating a vector index on the text in our Chunk nodes",
   "id": "4d7b98e310104246"
  },
  {
   "metadata": {},
   "cell_type": "code",
   "source": [
    "from neo4j_graphrag.indexes import create_vector_index\n",
    "\n",
    "create_vector_index(driver, name=\"text_embeddings\", label=\"Chunk\", embedding_property=\"embedding\", dimensions=1536, similarity_fn=\"cosine\")"
   ],
   "id": "940b051107b89204",
   "outputs": [],
   "execution_count": null
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "Now that the index is set up we will start simple with a VectorRetriever.  The VectorRetriever just queries Chunk nodes, brining back the text and some metadata",
   "id": "ec95391c989ee694"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T12:18:32.227859Z",
     "start_time": "2024-10-04T12:18:31.386497Z"
    }
   },
   "cell_type": "code",
   "source": [
    "from neo4j_graphrag.retrievers import VectorRetriever\n",
    "\n",
    "from neo4j_graphrag.embeddings.openai import OpenAIEmbeddings\n",
    "\n",
    "embedder = OpenAIEmbeddings()\n",
    "\n",
    "vector_retriever = VectorRetriever(\n",
    "    driver,\n",
    "    index_name=\"text_embeddings\",\n",
    "    embedder=embedder,\n",
    "    return_properties=[\"text\"],\n",
    ")"
   ],
   "id": "eeda7e519c60a02b",
   "outputs": [],
   "execution_count": 9
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T12:24:50.785067Z",
     "start_time": "2024-10-04T12:24:50.022177Z"
    }
   },
   "cell_type": "code",
   "source": [
    "vector_res = vector_retriever.get_search_results(query_text = \"Which biomarkers are associated with predicting organ damage in lupus patients?\")\n",
    "\n",
    "for i in vector_res.records: print(\"====\\n\" + i.data()['node']['text'])"
   ],
   "id": "ca27731a1f99d71d",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "====\n",
      "se\n",
      "with active disease] or C3 levels [which fall when the disease\n",
      "is active] provide help to the clinician when assessing disease\n",
      "activity. Scoring is determined based on new, improving,\n",
      "worse and similar categories. The art of the physician is to\n",
      "identify the activity features clinically and apply the appro-\n",
      "priate management. Renal lupus can, rarely, be active without\n",
      "the presence of other SLE disease involvement. Cerebral lupus\n",
      "is scored in 20 separate sections from seizures to demyelina-\n",
      "tion. In patients with subacute presentations, it may be dif ﬁcult\n",
      "to assess and treat. Anti-dsDNA antibodies and complement\n",
      "can be normal in a proportion of cases.\n",
      "SLEDAI scoring systems are more limited in represen-\n",
      "tation of the features of lupus that are present. It provides\n",
      "a global score rather than distinguishing the organ systems\n",
      "and does not distinguish patients who are partly respond-\n",
      "ing, from those whose activity is unchanged or worse.\n",
      "Both SLEDAI and BILAG have been validated74,75\n",
      "Disease activity is more comprehensively assessed by\n",
      "BILAG and shown to be reliable and sensitive to change\n",
      "Manifestations such as gastrointestinal disease and haemoly-\n",
      "tic anaemia are not captured at all in SLEDAI.\n",
      "The precision of lupus care in the twenty- ﬁrst century\n",
      "is focused on minimizing the use of potent medication and\n",
      "the side-effects that they cause, while proactively treatingthe autoimmunity and preventing damage. Rituximab use\n",
      "is increasing but Belimumab (an anti-BAFF monoclonal)\n",
      "is currently only allowed by the National Institute of\n",
      "Clinical Excellence (NICE) for skin and joint disease\n",
      "only in the UK in BILAG centres. We recently reported\n",
      "on predictors of response.76These include the BILAG\n",
      "score and renal involvement. More severe disease had\n",
      "greater bene ﬁt from B-cell depletion. Patients need\n",
      "a careful balance of immunosuppression that controls the\n",
      "disease without rendering them too susceptible to infection\n",
      "and long-term risks such as increased cardiovascular risk.\n",
      "Our approach as detailed in Table 1 does not help in\n",
      "distinguishing subgroups of patients for methotrexate or\n",
      "azathioprine. The molecular tools for this are on their way\n",
      "to the clinic. In rheumatoid arthritis gene signature has\n",
      "been shown to assist response prediction.77\n",
      "In the current treatment of lupus longterm clinical and\n",
      "immunological remission is only achieved in a proportion\n",
      "of patients. The inherent pathophysiological complexity of\n",
      "lupus described at the cellular and molecular level cannot\n",
      "be overstated. Using targeted drug therapy and improving\n",
      "clinical assessment remains vital to improving disease\n",
      "control and patient outcomes.\n",
      "The Challenge of Moving T owards\n",
      "Precision Medicine in SLE\n",
      "As the foregoing text has con ﬁrmed the pathophysiological\n",
      "aspects of SLE are highly diverse and the combination of\n",
      "factors leading to say skin, kidney and renal disease are very\n",
      "different. In spite of these differences, a rather restricted set ofTable 2 Treatment Based on the Organ/Systemic Involved\n",
      "Example 1 2 3 4 5 6 7 8\n",
      "Constitutional\n",
      "SymptomsWidespread\n",
      "Discoid Lupus\n",
      "ErythematosusPolyarthritis Thrombo-\n",
      "cytopeniaLupus APS Arterial\n",
      "ThrombolysisMononeuritis\n",
      "MultiplexNephritis\n",
      "III/IVNephritis V\n",
      "1stLine HCQ/CS/ HCQ + CS HCQ + CS CS +\n",
      "HCQWarfarin/LMWH CS + IV Cyclo CS + MMF CS + MMF\n",
      "Immunomodulation\n",
      "2ndLine MMF ADD AZA ADD MTX AZA/MMF ADD aspirin/\n",
      "Dipyridamole/Platelet\n",
      "aggregation inhibitorADD Rituximab\n",
      "or IVIG/PEIV Cyclo →AZA/IV\n",
      "Cyclo or\n",
      "Rituximab\n",
      "3rdLine Rituximab/\n",
      "BelimumabAZA→MTX/\n",
      "BenlystaBenlysta/\n",
      "RituximabRituximab/\n",
      "IV Cyclo/\n",
      "IVIG/ / ADD\n",
      "Rituximab/\n",
      "Note: This table is based on the authors ’own experience.\n",
      "Abbreviations: CS, Corticosteroids; HCQ, Hydroxychloroquine, MTX, methotrexate; AZA, azathioprine; MMF , mycophenolate; Cyclo, Cyclophosphamide; LMWH, low\n",
      "molecular weight heparin; PE, plasma exchange.Dove press Lever et al\n",
      "Pharmacogenomics and Personalized Medicine 2020:13submit your manuscript | www.dovepress.com\n",
      "Dove Press45\n",
      "drugs steroids, immunosuppressives and Hydroxychloro\n",
      "====\n",
      "E, plasma exchange.Dove press Lever et al\n",
      "Pharmacogenomics and Personalized Medicine 2020:13submit your manuscript | www.dovepress.com\n",
      "Dove Press45\n",
      "drugs steroids, immunosuppressives and Hydroxychloroquine\n",
      "[seeTables 1 &2] are used with some success to treat these\n",
      "“diversely induced ”clinical features. Given that the mortality\n",
      "ﬁgures for lupus have improved from 50% 4-year survival in\n",
      "195078to approximately 90% 10-year survival now79these\n",
      "standard drugs have been bene ﬁcial. Some modest clues to\n",
      "precision targeting do exist with conventional drugs. Thus it\n",
      "has been shown that black lupus patients do not respond as\n",
      "well to Cyclophosphamide as Caucasians.80There is a debate\n",
      "about whether a seemingly well patient with a rising dsDNA\n",
      "antibody level and falling C3 should be treated prophylacti-\n",
      "cally as these markers anticipate a ﬂare.81However, as we\n",
      "have argued elsewhere the improvement in survival has lar-\n",
      "gely stalled82and it is likely that biologic drugs capable of\n",
      "targeting individual molecules will be needed to provide the\n",
      "kind of precise approach that precision medicine warrants.\n",
      "Sadly SLE lags far behind the precision approaches available\n",
      "for the treatment of rheumatoid arthritis where currently ﬁve-\n",
      "biologic/small molecule drugs [anti-TNF, anti-CD20, blocking\n",
      "the link between the antigen-presenting cell and the T-cell,\n",
      "anti-IL6/IL6 receptor and JAK-ST AT inhibition] are approved\n",
      "for treatment.81In SLE the approval by the Federal Drug\n",
      "Administration of Benlysta [anti-BAFF] in 2012 remains the\n",
      "only biologic to be allowed in the disease in the USA.82In the\n",
      "UK NHS England permits the use of Rituximab but both\n",
      "the American College of Rheumatology83and the European\n",
      "League Against Rheumatism84recommend its use in renal\n",
      "lupus. Our [unpublished] observations are that it often works\n",
      "quickly to correct haematological problems [thrombocytope-\n",
      "nia or haemolytic anaemia] but is much slower to bene ﬁtr e n a l\n",
      "disease.\n",
      "The prospects of other approaches such as the use of\n",
      "Anifrolumab85which blocks interferon αand Atacicept86\n",
      "which blocks two B-cell activation factors [BAFF and\n",
      "APRIL] also open up the possibilities for a more precise\n",
      "approach to the treatment of SLE.\n",
      "Predicting response to treatment could be improved in\n",
      "the future. In the case of belimumab high SLEDAI score\n",
      "and polyarthritis.87More precise information was gleaned\n",
      "with BAFF or APRIL although this is preclinical in\n",
      "utility.88,89For rituximab, the type of interferon signature\n",
      "helps to distinguish response.90Vital and colleagues found\n",
      "two signatures; A and B. Signature B is a set of nonclas-\n",
      "sical interferon genes which were better at predicting\n",
      "response. TNF-like weak inducer of apoptosis (TWEAK)\n",
      "is a proin ﬂammatory cytokine from the TNF superfamily\n",
      "that binds monogamously to its receptor Fn14. In a study\n",
      "of 110 patients, it was a useful predictor of response toinduction therapy in lupus nephritis.91For mycophenolate,\n",
      "there is no clear marker of response from a systematic\n",
      "review.92These studies encourage the view that ultimately\n",
      "SLE will be susceptible to a precision medicine approach.\n",
      "Conclusions\n",
      "We have analysed recent facets of the pathological and\n",
      "immunogenetic basis of lupus. The network of factors that\n",
      "drives organ selectivity and how the precise within indivi-\n",
      "duals conspires to cause the diverse clinical features\n",
      "remains a mystery. Current treatment can be approached\n",
      "in a more precise and systematic fashion as suggested here.\n",
      "Future care will involve molecular diagnostics throughout\n",
      "the patient timecourse to drive the least toxic combination\n",
      "of therapies. Recent evidence suggests a paradigm shift is\n",
      "on the way but it is hard to predict how fast it will come.\n",
      "Disclosure\n",
      "The authors report no con ﬂicts of interest in this work.\n",
      "References\n",
      "1. Lisnevskaia L, Murphy G, Isenberg DA. Systemic lupus\n",
      "erythematosus. Lancet .2014 ;384:1878 –1888. doi:10.1016/S0140-\n",
      "6736(14)60128-8\n",
      "2. Moulton VR. Sex hormones in acquired immunity and autoimmune\n",
      "disease. Front Immunol .2018 ;9:2\n",
      "====\n",
      "s help to de ﬁne the affected organ\n",
      "system. The condition is heterogeneous and can present in\n",
      "unusual ways. Most patients are given hydroxychloroquineand prednisolone accompanied by immunosuppressives. In\n",
      "Table 1 we indicate the general outline for the manage-\n",
      "ment of SLE in the treatment of different organ and\n",
      "systems. This is adapted from BSR guideline on SLE.72\n",
      "Use of the British Isles Lupus Assessment Group\n",
      "(BILAG) scoring system provides a comprehensive\n",
      "approach to managing patients with lupus72The assessor\n",
      "needs to de ﬁne activity accurately distinguishing clinical\n",
      "features due to activity, distinct from previous damage or\n",
      "complications of therapy to capture active disease cor-\n",
      "rectly. The multimodal facets of the BILAG allow classi-\n",
      "ﬁcation of mild, moderate and severe disease. Mild disease\n",
      "includes non-life threatening organ involvement, equiva-\n",
      "lent to SLEDAI <6 with one or more grade C scores or\n",
      "a single grade B. Treatment may include topical steroid,\n",
      "low dose oral steroid and/or hydroxychloroquine. In con-\n",
      "trast, patients with moderate disease require stronger sup-\n",
      "pression of the immune system and would consistently\n",
      "have BILAG scores of 2 Bs or more. The most severe\n",
      "disease BILAG A implies high dose steroid ( ≥20mg/day;\n",
      "intravenous or oral, and other immunosuppressive agents.\n",
      "Other therapies outlined in Table 2 (which designates\n",
      "treatments according to disease severity) include anticoa-\n",
      "gulation or antiplatelet therapy in antiphospholipid patients\n",
      "and the use of rituximab or cyclophosphamide as second-\n",
      "line treatments to induce remission.\n",
      "Patients with skin-limited disease usually respond to non-\n",
      "aggressive treatment including topical and oral steroids and\n",
      "hydroxychloroquine. We recently reported on the use of ritux-\n",
      "imab in severe cutaneous lupus73and showed that some types\n",
      "of subcutaneous lupus [e.g., acute cutaneous LE] respond\n",
      "Table 1 SLE Treatment Based on Severity of the Disease\n",
      "Mild Disease Moderate Disease Severe Disease\n",
      "[BILAG C Scores/Single B/SLEDAI ≤6] 2 or more BILAG Bs/SLEDAI 6-12 1 or more BILAG A/SLEDAI ≥12\n",
      "Features Fatigue, malar rash, diffuse alopecia, myalgia,\n",
      "platelets 50 –149 x 109/LFever, rash (< 2/9 body surface area),\n",
      "cutaneous vasculitis, renal, pleurisy,\n",
      "pericarditis, platelets 25 –49 x 109/LRash > 2/9 body surface area, severe pleurisy/\n",
      "pericarditis, psychosis, renal/myositis/platelets\n",
      "<2 5x1 09/L\n",
      "T ypical\n",
      "Drugs &\n",
      "T arget DosePrednisolone topical or <20mg/day for 1 –2\n",
      "weeks/IM or IA Methylprednisolone +HCQ\n",
      "≤6.5mg/kg ± NSAIDs maybe MethotrexatePrednisolone ≤0.5mg/kg/day or IV or IA\n",
      "Methylprednisolone +AZA 2mg/kg/day\n",
      "or MTX 10 –25mg/week or MMF 2 –3g/\n",
      "dayPrednisolone ≤0.5mg/kg/day and/or IV\n",
      "Methylprednisolone 500mg IV x 3) +AZA\n",
      "2-3mg/kg/day or MMF 2 –3g/day or IV Cyclo +\n",
      "HCQ 200mg/day\n",
      "Maintenance\n",
      "DosePrednisolone ≤7.5mg/day + HCQ 200mg/\n",
      "day ± Methotrexate 10mg/weekPrednisolone ≤7.5mg/day + AZA 50 –\n",
      "100mg/day or MTX 10mg/week or MMF\n",
      "1g/day +HCQ 200mg/dayPrednisolone ≤7.5mg/day + AZA 50 –100mg/day\n",
      "or MTX 10mg/week or MMF 1g/day +HCQ\n",
      "200mg/day\n",
      "Note: Based upon the guidelines of the British Society of Rheumatology.72\n",
      "Abbreviations: IM, Intramuscular; IV, intravenous; HCQ, Hydroxychloroquine, NSAIDs, nonsteroidal antiin ﬂammatory drugs; MTX, methotrexate; AZA, azathioprine;\n",
      "MMF , mycophenolate; Cyclo, Cyclophosphamide.Lever et al Dove press\n",
      "submit your manuscript | www.dovepress.com\n",
      "Dove PressPharmacogenomics and Personalized Medicine 2020:13 44\n",
      "better than other forms [e.g., subacute and chronic]. Severe\n",
      "life-threatening lupus with renal or neuropsychiatric involve-\n",
      "ment is treated with potent agents notably cyclophosphamide.\n",
      "BILAG grading and following the pattern over time assists in\n",
      "determining the degree of immunosuppression. Use of blood\n",
      "markers notably anti-dsDNA antibody levels [which increase\n",
      "with active disease] or C3 levels [which fall when the disease\n",
      "is active] provide help to the clinician when assessing disease\n",
      "activity. Scoring is determined based on new, improving,\n",
      "worse and sim\n",
      "====\n",
      " features of lupus nephritis. Medicine .2015 ;94:1 –8.\n",
      "doi:10.1097/MD.0000000000000829\n",
      "41. Yu F, Haas M, Glassock R, et al. Rede ﬁning lupus nephritis: clinical\n",
      "implications of pathophysiologic subtypes. Nat Rev Nephrol .\n",
      "2017 ;13:483 –495. doi:10.1038/nrneph.2017.85\n",
      "42. Londoño Jiminez A, Mowrey WB, Putternam C, Buyon J, Goilav B,\n",
      "Broder A. Brief report: tubulointerstitial damage in lupus nephritis:\n",
      "A comparison of the factors associated with tubulointerstitial in ﬂam-\n",
      "mation and renal scarring. Arthritis Rheumatol .2018 ;70:1801 –1806.\n",
      "doi:10.1002/art.40575\n",
      "43. Arazi A, Rao DA, Berthier CC etal,. The immune cell landscape in\n",
      "kidneys of patients with lupus nephritis. Nat Immunol .\n",
      "2019 ;20:902 –914. doi:10.1038/s41590-019-0398-x\n",
      "44. Yung S, Chan TM. Anti-dsDNA antibodies and resident renal cells -\n",
      "Their putative roles in pathogenesis of renal lesions in lupus nephritis.\n",
      "Clin Immunol .2017 ;185:40 –50 . doi:10.1016/j.clim.2016.09.002\n",
      "45. Nalewajska M, Gurazda K, Styczy ńska-Kowalska E, et al. The role\n",
      "of MicroRNAs in selected forms of glomerulonephritis. Int J Mol Sci .\n",
      "2019 ;20:1 –9. doi:10.3390/ijms20205050\n",
      "46. Sakhi H, Mokte ﬁA, Bouachi K, et al. Podocyte injury in lupus\n",
      "nephritis. J Clin Med .2019 ;8:1340. doi:10.3390/jcm8091340\n",
      "47. Mejía-Vilet JM, Córdova-Sánchez BM, Uribe-Uribe NO, Correa-\n",
      "Rotter R, Morales-Buenrostro LE. Prognostic signi ﬁcance of renal\n",
      "vascular pathology in lupus nephritis. Lupus .2017 ;26:1042 –1050.\n",
      "doi:10.1177/0961203317692419\n",
      "48. Jafri K, Patterson SL, Lanata C. Central nervous system manifesta-\n",
      "tions of systemic lupus erythematosus. Rheumatic Dis Clin N Am .\n",
      "2017 ;43:531 –548. doi:10.1016/j.rdc.2017.06.003\n",
      "49. Hanly J, Urowitz MB, Su L, et al. Autoantibodies as biomarkers for\n",
      "the prediction of neuropsychiatric events in systemic lupus\n",
      "erythematosus. Ann Rheum Dis .2011 ;10:1726 –1732. doi:10.1136/\n",
      "ard.2010.148502\n",
      "50. McGlasson S, Wiseman S, Wardlaw J, Dhaun N, Hunt DPJ.\n",
      "Neurological disease in lupus: toward a personalized medicine\n",
      "approach. Front Immunol .2018 ;9(1146):1 –12. doi:10.3389/ ﬁmmu.\n",
      "2018.01146\n",
      "51. Tchessalova D, Posillico CK, Tronson NC. Neuroimmune activation\n",
      "drives multiple brain states. Front Syst Neurosci .2018 ;12:39.\n",
      "doi:10.3389/fnsys.2018.00039Dove press Lever et al\n",
      "Pharmacogenomics and Personalized Medicine 2020:13submit your manuscript | www.dovepress.com\n",
      "Dove Press47\n",
      "52. Schwartz N, Stock AD, Putterman C. Neuropsychiatric lupus: new\n",
      "mechanistic insights and future treatment directions. Nat Rev\n",
      "Rheumatol .2019 ;15:137 –152. doi:10.1038/s41584-018-0156-8\n",
      "53. Stock AD, Ben-Zui A, Putterman C. Pathogenesis of neuropsychia-\n",
      "tric lupus. In: Wallace DJ, Hahn BH, editors. Dubois Lupus\n",
      "Erythematosus and Related Symptoms . 9th ed. Elsevier; 317.23.\n",
      "doi:10.1186/s13075-018-1604-1\n",
      "54. Julià A, López-Longo FJ, Pérez Venegas JJ, et al. Genome-wide\n",
      "association study meta-analysis identi ﬁesﬁve new loci for systemic\n",
      "lupus erythematosus. Arthritis Ther Res .2018 ;1(100):1 –10.\n",
      "doi:10.1186/s13075-018-1604-1\n",
      "55. Amlöf JC, Alexsson A, Imgenberg-Kreuz J, et al. Novel risk genes for\n",
      "systemic lupus erythematosus predicted by random forest classi ﬁcation.\n",
      "Sci Rep .2017 ;1(6236):1 –11. doi:10.1038/s41598-017-06516-1\n",
      "56. Catalina MD, Owen KA, Labonte AC, Grammer AC, Lipsky PE,\n",
      "Labonte AC. The pathogenesis of systemic lupus erythematosus:\n",
      "harnessing big data to understand the molecular basis of lupus.\n",
      "J Autoimmun .2019 ;2:102359. doi:10.1016/j.jaut.2019.102359\n",
      "57. Surace AEA, Hedrich CM. The role of epigenetics in autoimmune/\n",
      "inﬂammatory disease. Front Immunol .2019 . doi:10.3389/\n",
      "ﬁmmu.2019:01525\n",
      "58. Imgenberg-Kreuz J, Carlsson Almlöf J, Leonard D, et al. DNA\n",
      "methylation mapping identi ﬁes gene regulatory effects in patients\n",
      "with systemic lupus erythematosus. Ann Rheum Dis .2018 ;77\n",
      "(5):736 –743. doi:10.1136/annrheumdis-2017-212379\n",
      "59. Hedrich CM. Epigenetics in SLE. Curr Rheumatol Rep .2017 ;19\n",
      "(58):1 –13. doi:10.1007/s11926-017-0685-1\n",
      "60. Wang Z, Yin H, Lau CS, Lu Q. Histone posttranslational modi ﬁca\n",
      "====\n",
      "of methotrexate nonresponse in\n",
      "patients with rheumatoid arthritis. Arthritis Rheumatol .\n",
      "2019 ;71:678 –684. doi:10.1002/art.40810\n",
      "78. Merrell M, Shulman LE. Determination of prognosis in chronic\n",
      "disease illustrated by systemic lupus erythematosus. J Chronic Dis .\n",
      "1955 ;1:12 –32. doi:10.1016/0021-9681(55)90018-7\n",
      "79. Mak A, Cheung MW-L, Chiew KJ, et al. Global trend of survival\n",
      "and damage of systemic lupus erythematosus: meta-analysis and\n",
      "meta-regression of observational studies from the 1950s to 2000s.\n",
      "Semin Arthritis Rheum .2012 ;41:830 –839. doi:10.1016/j.semarthrit.\n",
      "2011.11.002\n",
      "80. Dooley MA, Hogan S, Falk R. Cyclophosphamide therapy for lupus\n",
      "nephritis: poor survival in black Ameri cans. glomerular disease collabora-\n",
      "tive network. Kidn Int .1997;51:1188 –1195. doi:10.1038/ki.1997.162\n",
      "81. Ciurtin C, Isenberg DA, Eds. Biologics in Rheumatology . New York:\n",
      "Nova Biomedical; 2016 .\n",
      "82. Van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the\n",
      "treatment of systemic lupus erythematosus: high disease activity\n",
      "predictions of response. Ann Rheum Dis .2012 ;71:1343 –1349.\n",
      "doi:10.1136/annrheumdis-2011-200937\n",
      "83. Hahn BH, McMahon MA, Wilkinson A, et al. American college of\n",
      "rheumatology guidelines for screening, treatment and management of\n",
      "lupus nephritis. Arthritis Care Res .2012;64:797 –808. doi:10.1002/\n",
      "acr.21664\n",
      "84. Bertsios G, Tektonidou M, Amura Z, et al. Joint European League\n",
      "Against Rheumatism and European Renal Association –European\n",
      "Dialysis and Transplant Association [EULAR/ERA-EDTA] recom-\n",
      "mendations for the management of adult and paediatric lupus nephri-\n",
      "tis.Ann Rheum Dis .2012 ;71:177 –182.\n",
      "85. Felten R, Scher F, Sagez F, Chasset F, Arnaud L. Spotlight on\n",
      "anifrolumab and its potential for the treatment of moderate-to-\n",
      "severe systemic lupus erythematosus: evidence to date. Drug Des\n",
      "Devel Ther .2019 ;13:1535 –1543. doi:10.2147/DDDT.S170969\n",
      "86. Merrill JT, Wallace DJ, Wax S, et al. Ef ﬁcacy and safety of Atacicept\n",
      "in patients with systemic lupus erythematosus. Arthritis Rheum .\n",
      "2018 ;70:266 –276. doi:10.1002/art.40360\n",
      "87. Laccarino L, Andreoli L, Bocci EB, et al. Clinical predictors of response\n",
      "and discontinuation of belimumab in patients with systemic lupus\n",
      "erythematosus in real life setting. Results of a large, multicentric, nation-\n",
      "wide study. J Autoimmun .2018;86:1 –8. doi:10.1016/j.jaut.2017.09.004\n",
      "88. Piantoni S, Andreoli L, Lowin T. Baseline serum levels of baff or\n",
      "april are independent predictors of sledai response after 12 months of\n",
      "treatment with belimumab in patients with refractory systemic lupus\n",
      "erythematosus. doi:10.1136/lupus-2018-abstract.43Lever et al Dove press\n",
      "submit your manuscript | www.dovepress.com\n",
      "Dove PressPharmacogenomics and Personalized Medicine 2020:13 48\n",
      "89. Parodis I, Johansson P, Gomez A, Soukka S, Emamikia S,\n",
      "Chatzidionysiou K, Gomez A. Predictors of low disease activity and\n",
      "clinical remission following belimumab treatment in systemic lupus\n",
      "erythematosus. Rheumatology (Oxford) .2019 ;58(12):2170 –2176.\n",
      "doi:10.1093/rheumatology/kez191\n",
      "90. Alase A, Wigston Z, Burska A. Prediction of response to rituximab in\n",
      "SLE using a validated two-score system for interferon status.\n",
      "doi:10.1136/lupus-2019-lsm.7191. Suttichet TB, Kittanamongkolchai W, Phromjeen C. Urine TWEAK\n",
      "level as a biomarker for early response to treatment in active lupus\n",
      "nephritis: a prospective multicentre study. Lupus Sci Med .2019 .\n",
      "eCollection 2019. doi:10.1136/lupus-2018-000298\n",
      "92. Mendoza-Pinto C, Pirone C, van der Windt DA. Can we identify who\n",
      "gets bene ﬁt or harm from mycophenolate mofetil in systemic lupus\n",
      "erythematosus? Syst Rev Semin Arthritis Rheum .2017 ;47:65 –76.\n",
      "Pharmacogenomics and Personalized Medicine Dove press\n",
      "Publish your work in this journal\n",
      "Pharmacogenomics and Personalized Medicine is an international,\n",
      "peer-reviewed, open access journal characterizing the in ﬂuence of\n",
      "genotype on pharmacology leading to the development of persona-\n",
      "lized treatment programs and individualized drug selection for\n",
      "improved safety\n"
     ]
    }
   ],
   "execution_count": 10
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": [
    "The GraphRAG Python Package offers a whole host of other useful retrieval covering different GraphRAG patterns (text2cypher, vector and/or full text + Cypher template, etc.).  and if none of those fit perfectly you can implement your own custom retrievers. \n",
    "\n",
    "Below we will use the VectorCypherRetriever which allows you to run a graph traversal after finding text chunks.  We will use the Cypher Query language to define the logic to traverse the graph.  \n",
    "\n",
    "As a simple starting point, lets traverse up to 2 hops out from each chunk and textualize the different relationships we pick up.  We will use something called a quantified path pattern to accomplish in this. "
   ],
   "id": "2b2ee3da2339365f"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T13:28:00.467158Z",
     "start_time": "2024-10-04T13:28:00.116410Z"
    }
   },
   "cell_type": "code",
   "source": [
    "from neo4j_graphrag.retrievers import VectorCypherRetriever\n",
    "\n",
    "vc_retriever=VectorCypherRetriever(\n",
    "    driver,\n",
    "    index_name=\"text_embeddings\",\n",
    "    embedder=embedder,\n",
    "    retrieval_query=\"\"\"\n",
    "MATCH (node)<-[:FROM_CHUNK]-()-[rl:!FROM_CHUNK]-{1,2}()\n",
    "UNWIND rl AS r\n",
    "WITH DISTINCT r\n",
    "MATCH (sourceDoc:Document)<-[FROM_DOCUMENT]-()<-[:FROM_CHUNK]-(n)-[r]->(m)\n",
    "WITH n,r,m, apoc.text.join(collect(DISTINCT sourceDoc.path), ', ') AS sources\n",
    "// return textualize relations\n",
    "RETURN n.name + '(' + coalesce(n.details, '') + ')'+ \n",
    "    ' - ' + type(r) + '(' + coalesce(r.details, '') + ')' +  ' -> ' + \n",
    "    m.name + '(' + coalesce(m.details, '') + ')' + ' [sourced from: ' + sources + ']' AS fact\n",
    "        \"\"\",\n",
    ")\n"
   ],
   "id": "caf84995e4bc8d4",
   "outputs": [],
   "execution_count": 28
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T13:28:01.767676Z",
     "start_time": "2024-10-04T13:28:00.602184Z"
    }
   },
   "cell_type": "code",
   "source": [
    "vc_res = vc_retriever.get_search_results(query_text = \"How do environmental factors influence systemic lupus erythematosus?\")\n",
    "for i in vc_res.records: print(\"====\\n\" + i.data()['fact']) "
   ],
   "id": "4a1df583f2450f35",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "====\n",
      "Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - DESCRIBES(The paper discusses the role of sex hormones in SLE.) -> Sex hormones in acquired immunity and autoimmune disease(A paper discussing the role of sex hormones in immunity and autoimmune diseases.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - DESCRIBES(The paper explores the relationship between stress and SLE.) -> The role of stress in the mosaic of autoimmunity: an overlooked association(A paper exploring the relationship between stress and autoimmunity.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - DESCRIBES(The review discusses the interaction between viruses and SLE.) -> Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms(A review discussing the interaction between viruses and autoimmune responses.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - DESCRIBES(The study examines the association between smoking and SLE.) -> Cigarette smoking and the risk of systemic lupus erythematosus(A study examining the association between smoking and the risk of developing SLE.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - DESCRIBES(The paper discusses the impact of environmental factors on SLE.) -> Environmental factors, toxicants and systemic lupus erythematosus(A paper discussing the impact of environmental factors on SLE.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - DESCRIBES(The paper investigates the influence of microbes and diet on SLE.) -> SLE: another autoimmune disorder influenced by microbes and diet?(A paper investigating the influence of microbes and diet on SLE.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - DESCRIBES(The study focuses on the classification criteria for SLE.) -> Derivation and validation of the systemic lupus erythematosus international collaborating clinics classification criteria(A study on the classification criteria for SLE.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - DESCRIBES(The paper updates the classification criteria for SLE.) -> Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus(A paper updating the classification criteria for SLE.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - DESCRIBES(The paper details the classification criteria for SLE by EULAR and ACR.) -> European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus(A paper detailing the classification criteria for SLE by EULAR and ACR.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - DESCRIBES(The study validates new classification criteria for SLE.) -> Validation of new systemic lupus erythematosus classification criteria(A study validating new classification criteria for SLE.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - DESCRIBES(The study assesses the performance of ACR-EULAR criteria for SLE.) -> Performance of the proposed ACR-EULAR classification criteria for systemic lupus erythematosus(A study assessing the performance of ACR-EULAR criteria for SLE.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - DESCRIBES(The paper updates management recommendations for SLE.) -> Update of the EULAR recommendations for the management of systemic lupus erythematosus(A paper updating management recommendations for SLE.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - DESCRIBES(The study analyzes remission rates in SLE patients.) -> Analysis of complete remission in systemic lupus erythematosus patients over a 32-year period(A study analyzing remission rates in SLE patients.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - DESCRIBES(The review discusses the role of apoptosis in immune regulation related to SLE.) -> Apoptosis and clearance of apoptotic cells(A review discussing the role of apoptosis in immune regulation.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - DESCRIBES(The paper discusses how neutrophils contribute to SLE pathogenesis.) -> The role of neutrophils in the pathogenesis of systemic lupus erythematosus(A paper discussing how neutrophils contribute to SLE pathogenesis.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - DESCRIBES(The study links low ROS production to SLE.) -> Low production of reactive oxygen species drives systemic lupus erythematosus(A study linking low ROS production to SLE.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - DESCRIBES(The paper discusses the role of neutrophils and NETosis in SLE.) -> An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus(A paper discussing the role of neutrophils and NETosis in SLE.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - DESCRIBES(The study focuses on the role of neutrophil extracellular traps in SLE.) -> Neutrophil extracellular traps(A study on the role of neutrophil extracellular traps in SLE.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Epigenetics in SLE(An article discussing the role of epigenetics in systemic lupus erythematosus.) - PUBLISHED_IN() -> Curr Rheumatol Rep(A journal focusing on rheumatology.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Epigenetics in SLE(An article discussing the role of epigenetics in systemic lupus erythematosus.) - CITES() -> Histone posttranslational modifications of CD4+ T cell in autoimmune diseases(A paper focusing on histone modifications in CD4+ T cells related to autoimmune diseases.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Histone posttranslational modifications of CD4+ T cell in autoimmune diseases(A paper focusing on histone modifications in CD4+ T cells related to autoimmune diseases.) - CITES() -> Ultraviolet B inhibition of DNMT1 activity(A study on how UVB affects DNMT1 activity in CD4+ T cells from SLE patients.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Ultraviolet B inhibition of DNMT1 activity(A study on how UVB affects DNMT1 activity in CD4+ T cells from SLE patients.) - CITES() -> The impact of vitamin D on the immunopathophysiology of systemic lupus erythematosus(A paper discussing the effects of vitamin D on SLE.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "The impact of vitamin D on the immunopathophysiology of systemic lupus erythematosus(A paper discussing the effects of vitamin D on SLE.) - CITES() -> How compelling are the data for Epstein-Barr virus being a trigger for systemic lupus and other autoimmune diseases?(A review discussing the potential link between Epstein-Barr virus and autoimmune diseases.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "How compelling are the data for Epstein-Barr virus being a trigger for systemic lupus and other autoimmune diseases?(A review discussing the potential link between Epstein-Barr virus and autoimmune diseases.) - CITES() -> mTOR and other effector kinase signals that impact T cell function and activity(A paper on the role of mTOR and other kinases in T cell function.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "mTOR and other effector kinase signals that impact T cell function and activity(A paper on the role of mTOR and other kinases in T cell function.) - CITES() -> Cyclophosphamide perturbs cytokine methylation in Jurkat-T cells(A study on the effects of cyclophosphamide on cytokine methylation.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Cyclophosphamide perturbs cytokine methylation in Jurkat-T cells(A study on the effects of cyclophosphamide on cytokine methylation.) - CITES() -> The microbiome in SLE pathogenesis(A review discussing the role of the microbiome in the pathogenesis of SLE.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "The microbiome in SLE pathogenesis(A review discussing the role of the microbiome in the pathogenesis of SLE.) - CITES() -> Recent advances in our understanding of the link between the intestinal microbiota and systemic lupus erythematosus(A paper on the relationship between gut microbiota and SLE.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Recent advances in our understanding of the link between the intestinal microbiota and systemic lupus erythematosus(A paper on the relationship between gut microbiota and SLE.) - CITES() -> Translocation of a gut pathobiont drives autoimmunity in mice and humans(A study on how gut pathobionts can trigger autoimmunity.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Translocation of a gut pathobiont drives autoimmunity in mice and humans(A study on how gut pathobionts can trigger autoimmunity.) - CITES() -> Control of lupus nephritis by changes of gut microbiota(A study on how gut microbiota changes can affect lupus nephritis.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Control of lupus nephritis by changes of gut microbiota(A study on how gut microbiota changes can affect lupus nephritis.) - CITES() -> Commensal orthologs of the human autoantigen Ro60 as triggers of autoimmunity in lupus(A paper discussing the role of commensal bacteria in triggering autoimmunity.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Commensal orthologs of the human autoantigen Ro60 as triggers of autoimmunity in lupus(A paper discussing the role of commensal bacteria in triggering autoimmunity.) - CITES() -> Association of polyphenols from oranges and apples with specific intestinal microorganisms in systemic lupus erythematosus patients(A study on the association between polyphenols and gut microbiota in SLE patients.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Association of polyphenols from oranges and apples with specific intestinal microorganisms in systemic lupus erythematosus patients(A study on the association between polyphenols and gut microbiota in SLE patients.) - CITES() -> The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults(Guidelines for managing SLE in adults.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults(Guidelines for managing SLE in adults.) - CITES() -> Assessment of response to B-cell depletion using Rituximab in cutaneous lupus erythematosus(A study assessing the effectiveness of Rituximab in cutaneous lupus.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Assessment of response to B-cell depletion using Rituximab in cutaneous lupus erythematosus(A study assessing the effectiveness of Rituximab in cutaneous lupus.) - CITES() -> Measures of adult systemic lupus erythematosus(A paper discussing various measures for assessing SLE in adults.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Measures of adult systemic lupus erythematosus(A paper discussing various measures for assessing SLE in adults.) - CITES() -> BILAG 2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000(A study comparing disease activity indices for SLE.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "BILAG 2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000(A study comparing disease activity indices for SLE.) - CITES() -> Why do some patients with systemic lupus erythematosus fail to respond to B-cell depletion using rituximab?(A paper exploring reasons for non-response to Rituximab in SLE patients.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Why do some patients with systemic lupus erythematosus fail to respond to B-cell depletion using rituximab?(A paper exploring reasons for non-response to Rituximab in SLE patients.) - CITES() -> Proﬁling of gene expression biomarkers as a classifier of methotrexate nonresponse in patients with rheumatoid arthritis(A study on gene expression biomarkers in rheumatoid arthritis.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine(The journal in which the article was published.) - PUBLISHED_IN(Research on SLE is published in the journal Pharmacogenomics and Personalized Medicine.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Towards Precision Medicine in Systemic Lupus Erythematosus(A review article discussing systemic lupus erythematosus (SLE) and the challenges in applying precision medicine.) - PUBLISHED_IN() -> Pharmacogenomics and Personalized Medicine(The journal in which the article was published.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Towards Precision Medicine in Systemic Lupus Erythematosus(A review article discussing systemic lupus erythematosus (SLE) and the challenges in applying precision medicine.) - AUTHORED() -> Elliott Lever(One of the authors of the article.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Towards Precision Medicine in Systemic Lupus Erythematosus(A review article discussing systemic lupus erythematosus (SLE) and the challenges in applying precision medicine.) - AUTHORED() -> Marta R Alves(One of the authors of the article.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Towards Precision Medicine in Systemic Lupus Erythematosus(A review article discussing systemic lupus erythematosus (SLE) and the challenges in applying precision medicine.) - AUTHORED() -> David A Isenberg(One of the authors of the article.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Towards Precision Medicine in Systemic Lupus Erythematosus(A review article discussing systemic lupus erythematosus (SLE) and the challenges in applying precision medicine.) - ASSOCIATED_WITH() -> Systemic Lupus Erythematosus(A chronic, complex autoimmune disease characterized by multiorgan involvement.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - ASSOCIATED_WITH(B cells play a central role in the pathophysiology of SLE.) -> B cells(A type of white blood cell that plays a central role in the immune response.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "B cells(A type of white blood cell that plays a central role in the immune response.) - EXPRESSES(B cells that secrete IL-10 are functionally impaired in SLE.) -> IL-10(A regulatory cytokine secreted by B cells that is functionally impaired in SLE.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "B cells(A type of white blood cell that plays a central role in the immune response.) - HAS_SYMPTOM(Increased autoreactivity is observed in early immature B cells in SLE.) -> Increased autoreactivity(Early immature B cells in SLE patients show increased reactivity to self-antigens.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Ro60 antigen(An antigen that stimulates immune cells and is associated with SLE.) - INDUCES(Ro60 antigen induces the activation of B cells.) -> B cells(A type of white blood cell that plays a central role in the immune response.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - ASSOCIATED_WITH(T lymphocytes are central to the pathophysiology of SLE.) -> T lymphocytes(A type of white blood cell that is central to the adaptive immune system.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "T lymphocytes(A type of white blood cell that is central to the adaptive immune system.) - MANIFESTS_AS(T-cells in SLE patients are hyperactive.) -> Hyperactive T-cells(T-cells that are overactive and maintain expression of CD40 ligand longer than normal.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "T lymphocytes(A type of white blood cell that is central to the adaptive immune system.) - HAS_SYMPTOM(Impaired IL-2 production is a symptom in SLE.) -> Impaired IL-2 production(Reduced production of IL-2, which is important for Treg cell function.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "T lymphocytes(A type of white blood cell that is central to the adaptive immune system.) - HAS_SYMPTOM(Defective Treg cells are a symptom in SLE.) -> Defective Treg cells(Treg cells that are either deficient or dysfunctional in SLE patients.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "T lymphocytes(A type of white blood cell that is central to the adaptive immune system.) - RESULTS_IN(Aberrant TCR signaling can result from defects in T lymphocytes.) -> Aberrant T cell receptor (TCR) signaling(Altered signaling in T cells that can be induced by SLE serum IgG.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "T lymphocytes(A type of white blood cell that is central to the adaptive immune system.) - PART_OF(T lymphocytes mature in the thymus.) -> Thymus(An organ where T cells mature and undergo selection.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - ASSOCIATED_WITH(DNA methylation is linked to the pathogenesis of SLE.) -> DNA Methylation(A process that involves the addition of a methyl group to DNA, affecting gene expression.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "DNA Methylation(A process that involves the addition of a methyl group to DNA, affecting gene expression.) - EXPRESSES(DNA methylation affects the expression of IL-2.) -> IL-2(A cytokine that plays a central role in the regulation of immune responses.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "DNA Methylation(A process that involves the addition of a methyl group to DNA, affecting gene expression.) - EXPRESSES(DNA methylation affects the expression of FOXP3.) -> FOXP3(A transcription factor crucial for the development and function of regulatory T cells.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "miR-146a(A microRNA involved in the regulation of immune responses and linked to type-1 interferon gene expression.) - LINKED_TO(miR-146a is linked to DNA methylation processes.) -> DNA Methylation(A process that involves the addition of a methyl group to DNA, affecting gene expression.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Gut Microbiota Dysbiosis(An imbalance in the gut microbiota that has been observed in SLE patients.) - ASSOCIATED_WITH(Gut microbiota dysbiosis is associated with SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - TREATMENT_FOR(Belimumab is used to treat SLE.) -> Belimumab(A drug used to treat SLE by blocking BLyS/BAFF.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Belimumab(A drug used to treat SLE by blocking BLyS/BAFF.) - TREATMENT_FOR(Belimumab is used as a treatment for Systemic Lupus Erythematosus.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - TREATMENT_FOR(Rituximab is used for B cell depletion in SLE patients.) -> Rituximab(A drug used for B cell depletion in SLE patients.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - TREATMENT_FOR(Antimalarials are used in the treatment of SLE.) -> Antimalarials(Medications shown to be beneficial in most SLE patients.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - TREATMENT_FOR(Glucocorticoids are used in the treatment of SLE.) -> Glucocorticoids (GC)(A class of steroid hormones used in the treatment of SLE.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - TREATMENT_FOR(Immunosuppressants are used in the treatment of SLE.) -> Immunosuppressants (IS)(Medications that suppress or reduce the strength of the body's immune system.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Rituximab(A drug used for B cell depletion in SLE patients.) - TREATMENT_FOR(Rituximab is used as a treatment for Systemic Lupus Erythematosus.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Hydroxychloroquine(A type of drug used to treat various clinical features of SLE.) - TREATMENT_FOR(Hydroxychloroquine is used as a treatment for Systemic Lupus Erythematosus.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Methotrexate(A medication used in cancer treatment and autoimmune diseases.) - TREATMENT_FOR(Methotrexate is used as a treatment for Systemic Lupus Erythematosus.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Azathioprine(An immunosuppressive medication used in autoimmune diseases.) - TREATMENT_FOR(Azathioprine is used as a treatment for Systemic Lupus Erythematosus.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Mycophenolate(An immunosuppressive drug used to prevent organ rejection and treat autoimmune diseases.) - TREATMENT_FOR(Mycophenolate is used as a treatment for Systemic Lupus Erythematosus.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - INVOLVES(The pathophysiology of SLE involves various biological processes.) -> Pathophysiology of SLE(The study of the functional changes that accompany SLE.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - INVOLVES(The treatment of SLE involves immunosuppression.) -> Immunosuppression(A process involved in the treatment of SLE to reduce immune response.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - MANIFESTS_AS(SLE can manifest as clinical and immunological remission.) -> Clinical and immunological remission(A state where there is no clinical activity and normal antibody levels.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - ASSESSES(Precision medicine assesses SLE patients to tailor treatment.) -> Precision medicine(A tailored approach to treatment based on individual patient characteristics.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - ASSESSES(Disease activity in SLE can be assessed using blood markers.) -> Disease Activity(The level of activity in SLE, which can be assessed using blood markers.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Disease Activity(The level of activity in SLE, which can be assessed using blood markers.) - ASSESSES(Disease activity is assessed in patients with Systemic Lupus Erythematosus.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Belimumab(A drug used to treat SLE by blocking BLyS/BAFF.) - PARTICIPATES_IN(Belimumab is used in the treatment of SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Rituximab(A drug used for B cell depletion in SLE patients.) - PARTICIPATES_IN(Rituximab is used in the treatment of SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Cyclophosphamide(A chemotherapy drug that also has immunosuppressive properties.) - PARTICIPATES_IN(Cyclophosphamide is used in the treatment of SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - AFFECTS(SLE affects the process of apoptosis.) -> Apoptosis(The process of programmed cell death that is dysregulated in SLE.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "British Society of Rheumatology Guidelines(Guidelines that outline the management of SLE.) - CLASSIFIES(The British Society of Rheumatology Guidelines classify the management of SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Infections(Known risk factors that can exacerbate SLE.) - TRIGGERS(Infections can trigger SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Ultraviolet light(A known risk factor that can trigger SLE.) - TRIGGERS(Ultraviolet light is a known trigger for SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Toxins(Substances that can increase the apoptotic burden in SLE patients.) - TRIGGERS(Toxins are known to trigger SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Ultraviolet Exposure(Exposure to UV radiation, which has been linked to SLE.) - TRIGGERS(Ultraviolet exposure is associated with triggering SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - CAUSES(SLE leads to loss of self-tolerance in T and B cells.) -> Loss of self-tolerance(A condition where the immune system fails to recognize its own cells, leading to autoimmune diseases.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - USES(Rituximab is used as a second-line treatment for severe SLE.) -> Rituximab(A drug used for B cell depletion in SLE patients.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - USES(Hydroxychloroquine is used in the treatment of SLE.) -> Hydroxychloroquine(A type of drug used to treat various clinical features of SLE.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - USES(Cyclophosphamide is used to treat severe life-threatening lupus.) -> Cyclophosphamide(A chemotherapy drug that also has immunosuppressive properties.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - USES(Prednisolone is used in the treatment of SLE.) -> Prednisolone(A corticosteroid used to suppress the immune system in SLE patients.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - TARGETS(A low-disease activity state is a treatment target for SLE.) -> Low-disease activity state(A treatment target defined by specific disease activity index scores.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Rituximab(A drug used for B cell depletion in SLE patients.) - TREATMENT_FOR(Rituximab is used for treating renal lupus, a form of systemic lupus erythematosus.) -> Systemic Lupus Erythematosus(An autoimmune disease characterized by a wide range of clinical features and complications.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Benlysta(The first biologic drug approved for the treatment of SLE in the USA.) - TREATMENT_FOR(Benlysta is used as a treatment for systemic lupus erythematosus.) -> Systemic Lupus Erythematosus(An autoimmune disease characterized by a wide range of clinical features and complications.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Anifrolumab(A drug that blocks interferon α, proposed for a more precise treatment approach for SLE.) - TREATMENT_FOR(Anifrolumab is proposed for a more precise treatment approach for systemic lupus erythematosus.) -> Systemic Lupus Erythematosus(An autoimmune disease characterized by a wide range of clinical features and complications.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Atacicept(A drug that blocks two B-cell activation factors, BAFF and APRIL, for SLE treatment.) - TREATMENT_FOR(Atacicept is proposed for a more precise treatment approach for systemic lupus erythematosus.) -> Systemic Lupus Erythematosus(An autoimmune disease characterized by a wide range of clinical features and complications.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "BAFF(A B-cell activating factor involved in the immune response, relevant in SLE treatment.) - EXPRESSES(BAFF is expressed in the context of systemic lupus erythematosus.) -> Systemic Lupus Erythematosus(An autoimmune disease characterized by a wide range of clinical features and complications.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "APRIL(A protein that works alongside BAFF in B-cell activation, significant in SLE.) - EXPRESSES(APRIL is expressed in the context of systemic lupus erythematosus.) -> Systemic Lupus Erythematosus(An autoimmune disease characterized by a wide range of clinical features and complications.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "TWEAK(A pro-inflammatory cytokine that binds to its receptor Fn14, associated with SLE treatment response.) - EXPRESSES(TWEAK is expressed in the context of systemic lupus erythematosus.) -> Systemic Lupus Erythematosus(An autoimmune disease characterized by a wide range of clinical features and complications.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Response to Treatment(The outcome of treatment in patients with SLE, which can be predicted by various markers.) - HAS_EFFECT(Response to treatment is an important outcome in systemic lupus erythematosus.) -> Systemic Lupus Erythematosus(An autoimmune disease characterized by a wide range of clinical features and complications.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "B-cell(A type of immune cell involved in the pathogenesis of SLE and targeted by certain drugs.) - INTERACTS_WITH(B-cells interact with various factors in the pathogenesis of systemic lupus erythematosus.) -> Systemic Lupus Erythematosus(An autoimmune disease characterized by a wide range of clinical features and complications.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine(An open access journal characterizing the influence of genotype on pharmacology.) - DESCRIBES(The article discusses systemic lupus erythematosus.) -> Systemic Lupus Erythematosus(An autoimmune disease characterized by a wide range of clinical features and complications.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Hydroxychloroquine(A type of drug used to treat various clinical features of SLE.) - USED_FOR() -> Systemic Lupus Erythematosus(A chronic, complex autoimmune disease characterized by multiorgan involvement.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Lupus Nephritis(A significant glomerulonephritis that develops in up to 50% of SLE patients.) - ASSOCIATED_WITH(Lupus nephritis is a complication associated with systemic lupus erythematosus.) -> Systemic Lupus Erythematosus(A chronic, complex autoimmune disease characterized by multiorgan involvement.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Neuropsychiatric SLE(A group of syndromes affecting the central and peripheral nervous system in SLE patients.) - ASSOCIATED_WITH(Neuropsychiatric SLE is associated with systemic lupus erythematosus.) -> Systemic Lupus Erythematosus(A chronic, complex autoimmune disease characterized by multiorgan involvement.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Systemic Lupus International Collaborating Clinics(Developed a set of classification criteria for SLE.) - DEVELOPED() -> Systemic Lupus Erythematosus(A chronic, complex autoimmune disease characterized by multiorgan involvement.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "European League against Rheumatism(Collaborated in developing classification criteria for SLE.) - COLLABORATES_WITHCONTRIBUTES_TO() -> Systemic Lupus Erythematosus(A chronic, complex autoimmune disease characterized by multiorgan involvement.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "American College of Rheumatology(Collaborated in developing classification criteria for SLE.) - COLLABORATES_WITHCONTRIBUTES_TO() -> Systemic Lupus Erythematosus(A chronic, complex autoimmune disease characterized by multiorgan involvement.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Steroids(A type of drug used to treat various clinical features of SLE.) - USED_FOR() -> Systemic Lupus Erythematosus(A chronic, complex autoimmune disease characterized by multiorgan involvement.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Immunosuppressives(A type of drug used to treat various clinical features of SLE.) - USED_FOR() -> Systemic Lupus Erythematosus(A chronic, complex autoimmune disease characterized by multiorgan involvement.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Cyclophosphamide(A chemotherapy drug that also has immunosuppressive properties.) - INDUCES(Cyclophosphamide induces the expression of DNMT1.) -> DNMT1(A DNA methyltransferase enzyme that adds methyl groups to DNA.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Apoptosis(The process of programmed cell death that is dysregulated in SLE.) - PRODUCES(Apoptosis produces microparticles.) -> Microparticles(Small membrane vesicles that circulate in blood and are associated with apoptotic cells.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Microparticles(Small membrane vesicles that circulate in blood and are associated with apoptotic cells.) - INTERACTS_WITH(Microparticles can interact with anti-DNA antibodies to form immune complexes.) -> Immune complexes (IC)(Formed when microparticles react with anti-DNA antibodies.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "BLyS(A cytokine that may induce loss of tolerance in B cells.) - INDUCES(BLyS may induce loss of tolerance in B cells.) -> Loss of self-tolerance(A condition where the immune system fails to recognize its own cells, leading to autoimmune diseases.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine(An open access journal characterizing the influence of genotype on pharmacology.) - AUTHORED(The article is authored by Lever et al.) -> Lever et al(Authors of the article.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine(An open access journal characterizing the influence of genotype on pharmacology.) - PUBLISHED_IN(The article is published in Dove Press.) -> Dove Press(Publisher of the journal.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine(An open access journal characterizing the influence of genotype on pharmacology.) - CITES(The article cites the American Chemical Society's Chemical Abstracts Service.) -> American Chemical Society(An organization that indexes the journal in its Chemical Abstracts Service.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Mesangial Cells(Cells in the kidney that have a high regenerative capacity.) - PARTICIPATES_IN(Mesangial cells are involved in the pathophysiology of lupus nephritis.) -> Lupus Nephritis(A significant glomerulonephritis that develops in up to 50% of SLE patients.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "B Cells(A type of immune cell that is activated locally in lupus nephritis.) - PARTICIPATES_IN(B cells are activated in the renal parenchyma during lupus nephritis.) -> Lupus Nephritis(A significant glomerulonephritis that develops in up to 50% of SLE patients.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "T Cells(A type of immune cell involved in the pathogenic network of lupus nephritis.) - PARTICIPATES_IN(T cells interact with other immune cells in the pathogenic network of lupus nephritis.) -> Lupus Nephritis(A significant glomerulonephritis that develops in up to 50% of SLE patients.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Afro-Caribbean Patients(A demographic group that is more likely to develop lupus nephritis.) - LINKED_TO(Afro-Caribbean patients are more likely to develop lupus nephritis.) -> Lupus Nephritis(A significant glomerulonephritis that develops in up to 50% of SLE patients.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Prognosis(The likely course or outcome of a disease.) - AFFECTS(The prognosis of lupus nephritis is influenced by its classification.) -> Lupus Nephritis(A significant glomerulonephritis that develops in up to 50% of SLE patients.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Lupus Nephritis(A significant glomerulonephritis that develops in up to 50% of SLE patients.) - HAS_SYMPTOM(Podocyte damage is a symptom associated with lupus nephritis.) -> Podocyte Damage(Damage to podocytes that can occur due to immune complexes in lupus nephritis.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "International Society of Nephrology/Renal Pathology Society Classification(A classification system for glomerulonephritis focusing on glomerular lesions.) - CLASSIFIES(The classification system focuses on glomerular lesions in lupus nephritis.) -> Lupus Nephritis(A significant glomerulonephritis that develops in up to 50% of SLE patients.) [sourced from: pgpm-13-39.pdf]\n",
      "====\n",
      "Endothelial Activation(A process that can lead to complement activation and cellular recruitment in lupus nephritis.) - RESULTS_IN(Endothelial activation can lead to the development of lupus nephritis.) -> Lupus Nephritis(A significant glomerulonephritis that develops in up to 50% of SLE patients.) [sourced from: pgpm-13-39.pdf]\n"
     ]
    }
   ],
   "execution_count": 29
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T13:28:01.772574Z",
     "start_time": "2024-10-04T13:28:01.769242Z"
    }
   },
   "cell_type": "code",
   "source": "len(vc_res.records)",
   "id": "750f7fa9b7112ba7",
   "outputs": [
    {
     "data": {
      "text/plain": [
       "123"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "execution_count": 30
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": [
    "## GraphRAG Pipelines\n",
    " You can construct GraphRAG pipelines with the `GraphRAG` class.  At minimum, you will need to pass the constructor an LLM and a retriever. You can also pass a custom prompt template, but for now we will just use the default.\n",
    " "
   ],
   "id": "f2e55b8b3511cf1"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T13:28:04.316454Z",
     "start_time": "2024-10-04T13:28:04.272868Z"
    }
   },
   "cell_type": "code",
   "source": [
    "from neo4j_graphrag.llm import OpenAILLM as LLM\n",
    "from neo4j_graphrag.generation.graphrag import GraphRAG\n",
    "\n",
    "llm = LLM(model_name=\"gpt-4o\",  model_params={\"temperature\": 0})\n",
    "\n",
    "vc_rag = GraphRAG(llm=llm, retriever=vc_retriever)"
   ],
   "id": "8e2cf317a83d59ae",
   "outputs": [],
   "execution_count": 31
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "Lets start with  simple question and compare the answers for each",
   "id": "e772c5de32ef9bda"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T13:30:25.324329Z",
     "start_time": "2024-10-04T13:30:19.475917Z"
    }
   },
   "cell_type": "code",
   "source": [
    "q = \"What organ systems are most commonly affected by lupus?\"\n",
    "print(f\"\\n\\nVector + Cypher Response: \\n{vc_rag.search(q, retriever_config={'top_k':3}).answer}\")"
   ],
   "id": "477f00c916132357",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "Vector + Cypher Response: \n",
      "Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organ systems. The most commonly affected organ systems include:\n",
      "\n",
      "1. **Skin and Mucous Membranes**: SLE often causes skin rashes, including the characteristic \"butterfly rash\" on the face, as well as photosensitivity and oral ulcers.\n",
      "\n",
      "2. **Musculoskeletal System**: Joint pain and arthritis are common symptoms, affecting the joints and muscles.\n",
      "\n",
      "3. **Renal System**: Lupus nephritis, a significant form of kidney inflammation, develops in up to 50% of SLE patients.\n",
      "\n",
      "4. **Nervous System**: Neuropsychiatric SLE can affect both the central and peripheral nervous systems, leading to a variety of neurological and psychiatric symptoms.\n",
      "\n",
      "5. **Cardiovascular System**: SLE can lead to inflammation of the heart and blood vessels, increasing the risk of cardiovascular disease.\n",
      "\n",
      "6. **Respiratory System**: Inflammation of the lungs and pleura can occur, leading to pleuritis and other pulmonary complications.\n",
      "\n",
      "7. **Hematological System**: SLE can cause anemia, leukopenia, and thrombocytopenia due to its effects on blood cells.\n",
      "\n",
      "8. **Gastrointestinal System**: SLE can cause abdominal pain, nausea, and other gastrointestinal symptoms.\n",
      "\n",
      "These manifestations can vary widely among individuals, and the severity of organ involvement can range from mild to life-threatening.\n"
     ]
    }
   ],
   "execution_count": 39
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "Now lets try a bit more of a complex question",
   "id": "27fc4a28eec0d800"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T13:29:40.672478Z",
     "start_time": "2024-10-04T13:29:38.304519Z"
    }
   },
   "cell_type": "code",
   "source": [
    "q = \"How does precision medicine help in treating systemic lupus erythematosus (SLE)?\"\n",
    "print(f\"\\n\\nVector + Cypher Response: \\n{vc_rag.search(q).answer}\")"
   ],
   "id": "52bf2c3383f67352",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "Vector + Cypher Response: \n",
      "Precision medicine helps in treating systemic lupus erythematosus (SLE) by tailoring treatment based on individual patient characteristics. This approach involves assessing disease activity using blood markers and other patient-specific factors to customize therapy. Precision medicine aims to achieve clinical and immunological remission, where there is no clinical activity and normal antibody levels. By focusing on the unique aspects of each patient's condition, precision medicine seeks to improve treatment outcomes and manage SLE more effectively.\n"
     ]
    }
   ],
   "execution_count": 37
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "",
   "id": "461dad8755e55348"
  },
  {
   "metadata": {},
   "cell_type": "code",
   "source": "",
   "id": "b72a4184409b68ea",
   "outputs": [],
   "execution_count": null
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
